Jeff Geschwind, MD, is a physician scientist with a research focus on liver cancer and other GI malignancies. He is currently medical director of oncology, image-guided therapy, and imaging core lab at NAMSA, a prominent contract research organization, where he oversees all imaging protocols that are used for endpoints of clinical trials. Dr. Jeff Geschwind’s professional responsibilities also include his role as a medical advisor for HistoSonics where he is involved in clinical research activities and clinical procedure oversight. In addition, he is a consultant for Cage Pharma and is a member of the New Phase Scientific Advisory Board. Finally, as an expert in interventional oncology, he advises Philips Helathcare on new developments within this field.
Dr. Geschwind previously served as professor of radiology, surgery, and oncology at the Johns Hopkins University School of Medicine. He oversaw extensive growth in the Division of Vascular and Interventional Radiology’s research and clinical activities. He also guided the development of new and expanded state-of-the art facilities that have housed the division since 2012.
Dr. Geschwind has co-edited two books and authored nearly 300 scientific articles. His innovations in interventional oncology include the development of cone beam CT imaging to better visualize, target and more effectively treat liver tumors with intraarterial locoregional therapies. His pioneering work led to making cone beam CT the new standard of care for all intraarterial therapies. In recognition for his excellence in mresearch, he was invited to give the Wilhelm Conrad Roentgen Honorary Lecture at the European Congress of Radiology in Vienna in 2013 titled "Interventional Oncology: The Era of Molecular Targeted Therapy".
Dr. Geschwind’s professional recognitions include the American Roentgen Ray Society Scholar, as well as the Boston University School of Medicine Distinguished Alumnus Award among many others. He was selected as a Castle Connolly “Top Doctors in Cancer” for six consecutive years, and received the Albert Nelson Marquis Lifetime Achievement Award in 2019 for his lifetime scientific contributions.